← Back to Clinical Trials
Recruiting NCT06923657

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

Trial Parameters

Condition Prostate Cancer Screening
Sponsor First Affiliated Hospital of Fujian Medical University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 230
Sex MALE
Min Age 30 Years
Max Age 85 Years
Start Date 2025-05-07
Completion 2026-05-01
Interventions
PSMA PET/MRI-TRUS guided prostate targeted combined saturation biopsyTRUS guided transperineal saturation biopsy

Brief Summary

The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving early detection rates for csPCa and reducing missed diagnoses.

Eligibility Criteria

Inclusion Criteria: * Serum PSA \> 4 ng/mL * At least one prior negative prostate biopsy * At least two consecutive increases in PSA and/or PHI * Negative digital rectal examination * Multiparametric MRI (mpMRI) indicating a PI-RADS score ≤ 3 Exclusion Criteria * Age ≤ 30 years or \> 85 years * Concurrent presence of other malignant tumors * Previous treatment with any form of anti-tumor therapy or prostate surgery (excluding prostate biopsy) * Inability to comply with PSMA PET/MRI examination (e.g., contrast allergy, claustrophobia, etc.) * Contraindications for prostate biopsy (e.g., coagulation disorders, acute prostatitis, acute urinary tract infection, etc.) * Severe organ dysfunction (e.g., significant cardiac, pulmonary, hepatic, or renal impairment) * Incomplete clinical or pathological data

Related Trials